Scott Burrows - Arcutis Biotherapeutics CFO Officer

ARQT Stock  USD 16.42  1.80  12.31%   

Insider

Scott Burrows is CFO Officer of Arcutis Biotherapeutics
Age 47
Phone805 418 5006
Webhttps://www.arcutis.com

Scott Burrows Latest Insider Activity

Tracking and analyzing the buying and selling activities of Scott Burrows against Arcutis Biotherapeutics stock is an integral part of due diligence when investing in Arcutis Biotherapeutics. Scott Burrows insider activity provides valuable insight into whether Arcutis Biotherapeutics is net buyers or sellers over its current business cycle. Note, Arcutis Biotherapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Arcutis Biotherapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Arcutis Biotherapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2325) % which means that it has lost $0.2325 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1376) %, meaning that it created substantial loss on money invested by shareholders. Arcutis Biotherapeutics' management efficiency ratios could be used to measure how well Arcutis Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Arcutis Biotherapeutics currently holds 3.38 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. Arcutis Biotherapeutics has a current ratio of 10.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Arcutis Biotherapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Ian CritchleySpero Therapeutics
N/A
MBA CFABolt Biotherapeutics
61
Filip MDMonte Rosa Therapeutics
51
Rebecca SunshineCoherus BioSciences
62
Tom HolmesAmylyx Pharmaceuticals
N/A
Phil JDMonte Rosa Therapeutics
45
Stefan RileyInozyme Pharma
N/A
Demetrios MDInozyme Pharma
N/A
Henric BjarkeInozyme Pharma
57
PharmD ChiodinDay One Biopharmaceuticals
N/A
Jaa RobersonDay One Biopharmaceuticals
N/A
MD MBAAmylyx Pharmaceuticals
63
MBA JDApellis Pharmaceuticals
52
Paul RossMirum Pharmaceuticals
N/A
Julie MBADay One Biopharmaceuticals
42
Christopher SlavinskyCoherus BioSciences
51
Cedric MDApellis Pharmaceuticals
53
Aseem AnsariDesign Therapeutics
N/A
James BradySpero Therapeutics
N/A
Sharon TownsonMonte Rosa Therapeutics
50
Karen KotzCoherus BioSciences
N/A
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Arcutis Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 147 people. Arcutis Biotherapeutics (ARQT) is traded on NASDAQ Exchange in USA. It is located in 3027 Townsgate Road, Westlake Village, CA, United States, 91361 and employs 342 people. Arcutis Biotherapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Arcutis Biotherapeutics Leadership Team

Elected by the shareholders, the Arcutis Biotherapeutics' board of directors comprises two types of representatives: Arcutis Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcutis. The board's role is to monitor Arcutis Biotherapeutics' management team and ensure that shareholders' interests are well served. Arcutis Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcutis Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Patricia Turney, VP Operations
Todd Edwards, Executive Officer
Eric McIntyre, Head Relations
Ayisha Jeter, Head Access
David Osborne, Chief Officer
Bethany Dudek, Chief Officer
JD Esq, General VP
Todd Tucker, Vice Resources
Rajvir Madan, Chief Officer
Amanda Sheldon, Head Communications
Aleen Hosdaghian, Vice Marketing
Courtney Barton, VP Officer
Matthew Moore, Senior Officer
Scott Burrows, CFO Officer
Bhaskar Chaudhuri, CoFounder Director
Latha Vairavan, Vice Controller
Kent Taylor, Senior Sales
David Topper, Senior Officer
Todd MA, CEO President
John CPA, Interim Officer

Arcutis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcutis Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arcutis Stock Analysis

When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.